MX2009011495A - V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad. - Google Patents

V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad.

Info

Publication number
MX2009011495A
MX2009011495A MX2009011495A MX2009011495A MX2009011495A MX 2009011495 A MX2009011495 A MX 2009011495A MX 2009011495 A MX2009011495 A MX 2009011495A MX 2009011495 A MX2009011495 A MX 2009011495A MX 2009011495 A MX2009011495 A MX 2009011495A
Authority
MX
Mexico
Prior art keywords
cholerae
cholera toxin
hyperexpressing
recombinant cholera
immunogenicity
Prior art date
Application number
MX2009011495A
Other languages
English (en)
Inventor
Kenneth L Roland
Kevin P Killeen
Lawrence J Thomas
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of MX2009011495A publication Critical patent/MX2009011495A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se presentan composiciones inmunogénicas orales que imparten doble protección, contra Escherichia ccli que expresa la toxina lábil (LT) enterotoxigénica y contra Vibrio cholerae, con base en el suministro de antígeno toxina B de cólera recombinante por medio de vectores bacterianos vivos atenuados, derivados de Vibrio cholerae. Las composiciones tienen doble inmunogenicidad y retienen la capacidad para colonizar tejidos linfoides asociados a la mucosa gastrointestinal.
MX2009011495A 2007-04-24 2008-04-24 V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad. MX2009011495A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92612307P 2007-04-24 2007-04-24
PCT/US2008/005261 WO2008133926A1 (en) 2007-04-24 2008-04-24 V. cholerae hyperexpressing recombinant cholera toxin b subunit showing dual immunogenicity

Publications (1)

Publication Number Publication Date
MX2009011495A true MX2009011495A (es) 2010-02-15

Family

ID=39925978

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011495A MX2009011495A (es) 2007-04-24 2008-04-24 V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad.

Country Status (5)

Country Link
US (2) US8287855B2 (es)
CN (1) CN101730737B (es)
CA (1) CA2684742C (es)
MX (1) MX2009011495A (es)
WO (1) WO2008133926A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009011495A (es) * 2007-04-24 2010-02-15 Celldex Therapeutics Inc V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad.
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501351A (ja) 1987-10-07 1992-03-12 ワシントン ユニバーシティ 細胞の遺伝的集団において所望の組換え遺伝子を維持する方法
JP4179627B2 (ja) * 1992-07-06 2008-11-12 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ コレラワクチンとしての欠失変異体
US6203799B1 (en) 1993-07-01 2001-03-20 Presidents And Fellows Of Harvard College Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit
JPH11507532A (ja) 1995-06-07 1999-07-06 ワシントン ユニバーシティ 環境に制限される生存能を有する組換え細菌システム
JP4086945B2 (ja) * 1996-12-10 2008-05-14 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 非毒性Ｖ．Ｃｈｏｌｅｒａｅ株の単離法およびその株由来のコレラワクチンの製造法
SE515285C2 (sv) * 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
EP1543836A1 (en) 2003-12-17 2005-06-22 Berna Biotech AG Recombinant Vibrio cholerae strain and vaccine comprising said strain
MX2009011495A (es) * 2007-04-24 2010-02-15 Celldex Therapeutics Inc V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad.

Also Published As

Publication number Publication date
CN101730737B (zh) 2016-06-01
US8287855B2 (en) 2012-10-16
WO2008133926A1 (en) 2008-11-06
US20130122039A1 (en) 2013-05-16
CA2684742A1 (en) 2008-11-06
CN101730737A (zh) 2010-06-09
US20100129396A1 (en) 2010-05-27
CA2684742C (en) 2014-07-08

Similar Documents

Publication Publication Date Title
Jazayeri et al. Recent advances in delivery of veterinary DNA vaccines against avian pathogens
Walker et al. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
MX2009006178A (es) Vacuna contra salmonela.
Gayet et al. Vaccination against Salmonella infection: the mucosal way
EP2620157A3 (en) Vaccine nanotechnology
WO2009156405A8 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
EP2105129A3 (en) Encapsulated Vaccines for the Oral Vaccination and Boostering of Fish and Other Animals
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
WO2009103555A3 (en) Mucosal membrane receptor and uses thereof
WO2010037027A3 (en) Immunization of avians by mucosal administration of non-replicating vectored vaccines
MX2023003169A (es) Composiciones de vacunas multivalentes y usos de las mismas.
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
WO2007116102A3 (en) Therapeutic composition and use
MD20100029A2 (ro) Herpesvirus recombinant al crapului de koi (KHV) sau Cyprinid herpesvirus 3 (CyHV-3) şi vaccin pentru prevenirea bolii cauzate de KHV/CyHV-3 la Cyprinus carpio carpio sau Cyprinus carpio koi
WO2020039359A3 (en) Escherichia coli compositions and methods thereof
MX2009011495A (es) V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad.
MX2011003535A (es) Composiciones de virus de herpes bovino-1, vacunas, y metodos.
Yunle et al. Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants—A review
WO2009002372A3 (en) Prevention and treatment of gram negative, flagellated bacterial infections
WO2011100489A3 (en) Improved live bacterial vaccine safety
WO2011025344A3 (ko) 소의 병원성 대장균의 부착인자가 형질전환된 약독화 살모넬라균 변이주 및 이를 포함하는 소의 대장균증 및 살모넬라균증의 예방 및 치료용 백신조성물
WO2001089456A3 (en) Hybrid lt-a/ct-b holotoxin for use as an adjuvant
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
WO2009049013A3 (en) Cholera vaccines

Legal Events

Date Code Title Description
FG Grant or registration